Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Phosphatidylinositol 3-Kinases

abstract

  • The letrozole and buparlisib combination was safe, with reversible toxicities regardless of schedule administration. Clinical activity was observed independent of PIK3CA mutation status. No metabolic response by [(18)F]FDG-PET/CT scan at 2 weeks was associated with rapid disease progression. Phase III trials of buparlisib and endocrine therapy in patients with ER-positive breast cancer are ongoing.

publication date

  • April 20, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3986383

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.54.0518

PubMed ID

  • 24663045

Additional Document Info

start page

  • 1202

end page

  • 9

volume

  • 32

number

  • 12